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Purpose: To evaluate the TGFBI gene and the encoded transforming growth factor beta-induced protein (TGFBIp) in a
47-year-old African-American patient with an unusual atypical asymmetric lattice corneal dystrophy (LCD).
Methods: The eyes of the proband and his brother were examined by slit-lamp biomicroscopy and their clinical records
were reviewed. All 17 exons of TGFBI were evaluated in genomic DNA extracted from blood or buccal epithelial cell
samples from the proband and his family members. The corneal tissue of the proband was examined histopathologically,
and TGFBIp was analyzed in half of an excised corneal button.
Results: The proband (who had an unusual atypical asymmetric LCD) and his brother (who had mild bilateral deep stromal
opacities)  were  found  to  have  homozygous  Val624Met  mutations  in  TFGBI.  The  proband’s  daughter  who  was
heterozygous for the Val624Met mutation had no reported ophthalmic abnormalities. The corneal tissue from the proband
contained TGFBIp with the Val624Met mutation. Patients with LCD have different clinical phenotypes based on their
genotype. Molecular genetic analyses are becoming increasingly important in making precise diagnoses and prognostic
predictions about inherited corneal disorders.
Conclusions: A novel Val624Met homozygous mutation in TGFBI was associated with atypical LCD in two family
members. Symptomatic corneal disease was absent at the age of 24 years in the offspring of the proband who was
heterozygous for this mutation. This is an apparent example of a TGFBI mutation that becomes evident when it is
homozygous. The finding of Val624Met mutated TGFBIp in a ~65 kDa protein band in a reduced sodium dodecyl sulfate
(SDS) gel suggests that the accumulated protein was intact TGFBIp and not a fragment of TGFBIp.
The  lattice  corneal  dystrophies  (LCDs)  are  inherited
diseases  characterized  by  linear  opacities  composed  of
amyloid within the corneal stroma. The classic form of LCD
(LCD type 1), which is inherited as an autosomal dominant
trait, was originally described by Biber [1], Haab [2], and
Dimmer [3] in the late 1800s. Fine refractile lines in a lattice
meshwork appear in the anterior corneal stroma centrally and
spread to the periphery. This type of LCD typically presents
itself in the first decade of life with symptoms of recurrent
corneal erosions and decreased vision.
In 1992, the TGFBI (BIGH3) gene was identified by
Skonier et al. [4] in a study of genes induced by transforming
growth factor-β in a human adenocarcinoma cell line. Several
years later, Munier et al. [5] reported mutations in TGFBI in
several inherited corneal disorders with different phenotypes
including LCD type 1. Most frequently, LCD type I has been
associated with an Arg124Cys mutation in exon 4 of TGFBI
[5], but other mutations also cause this phenotype [6,7], other
variants  of  LCD,  or  corneal  amyloidosis.  Abnormal
accumulations of amyloid in corneas of affected patients are
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believed to contain either the transforming growth factor beta
induced protein (TGFBIp) or its degradation products.
Here, we report a novel mutation in TGFBI that was found
in a patient with an atypical asymmetric form of LCD.
METHODS
Duke University Institutional Review Board approval was
obtained for this study, which adhered to the tenets of the
Declaration of Helsinki.
Initially, a patient with unilateral linear corneal opacities
was referred to Duke University Eye Center. The proband and
his  brother  were  evaluated  clinically  by  slit-lamp
biomicroscopy. Available clinical records, family history, and
photographs  were  reviewed.  The  proband  underwent  a
penetrating  keratoplasty,  and  a  histopathologic  study  was
performed on the excised corneal button. This tissue specimen
was  sectioned  and  stained  with  hematoxylin  and  eosin,
Masson  trichrome,  periodic  acid  Schiff,  and  Congo  red.
Transmission electron microscopy was not performed. Half
of the proband’s cornea was frozen for protein analysis. This
was done after the specimen was lyophilized, homogenized,
and boiled in sample buffer at a concentration of 2 mg/ml
[8]. The sample was reduced with dithiothreitol (DTT) and
loaded on sodium dodecyl sulfate (SDS–PAGE) at 100 µg per
lane. The band containing TGFBIp was excised and digested
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495with trypsin. The released peptides were micropurified and
subjected to mass spectrometry on a quadrupole time-of-flight
instrument (Q-TOF Ultima Global, Micromass, Manchester,
UK)  equipped  with  both  MALDI  (matrix-assisted  laser
desorption ionization) and nanoelectrospray ion sources.
Buccal swabs were obtained from the proband’s 24-year-
old daughter who reportedly had no ocular disease. DNA was
extracted from venous blood or buccal swabs of all three
subjects. DNA from blood was obtained using the Puregene™
Blood  Kit  (Gentra  Systems,  Minneapolis,  MN)  and  from
buccal swabs using the PuregeneTM buccal cell kit (Gentra
Systems).  Genomic  DNA  of  all  exons  of  TGFBI  was
amplified  by  the  polymerase  chain  reaction  (PCR)  using
forward and reverse primers as documented elsewhere [9].
The resulting PCR products were purified using QIAquick®
PCR Purification Kit (Qiagen, Valencia, CA), sequenced on
both strands using the Big Dye Terminator Cycle Sequencing
system (Applied Biosystems, Foster City, CA), and combined
with an ABI 377 Prism DNA Sequencing instrument (Applied
Biosystems). The resulting DNA sequencing gel was analyzed
using  the  ABI  Prism  DNA  Sequence  Analysis  software
program  (Applied  Biosystems).  The  sequences  were  then
aligned  to  TGFBI  cDNA  using  the  SeqWeb,  Sequence
Analysis web-based program (Accelrys, San Diego, CA) to
look for any nucleotide changes and amino acid changes in
the sequences when compared to TGFBI cDNA. The entire
coding region of TGFBI was sequenced with this technique
as described elsewhere [6].
RESULTS
Clinical findings: The 47-year-old proband was hospitalized
for corneal transplantation. He had noted decreased vision for
several years before presentation; however, he had no prior
documented eye examination. At the time of the penetrating
keratoplasty, his best corrected visual acuity in the right eye
was  20/30  and  in  the  left  eye  was  20/50.  Slit  lamp
biomicroscopy of the proband revealed unilateral thick, ropy
linear opacities within the deep stroma of the left cornea
(Figure 1A,B). His fellow eye contained small, deep, short rod
shaped corneal stromal opacities, and both corneas of his
brother (44 years of age) were found to have bilateral corneal
opacities similar to those in the proband’s right cornea (Figure
1C,D).  The  proband’s  24-year-old  daughter  reported  no
ophthalmic symptoms by history and was unfortunately not
available for a clinical examination of her eyes. The proband
died of complications of chronic alcoholism at 49 years of age.
Histopathology: Histopathologic evaluation of the excised
corneal button revealed stromal deposits of amyloid, which
was confirmed in Congo red stained preparations examined
under polarized light. In keeping with the clinical impression,
the amyloid was not located in the superficial corneal stroma
but was found mainly in the mid-third of the corneal button.
Genetic analysis: The proband had a homozygous nucleotide
substitution of adenosine for guanine at nucleotide 1870 in
TGFBI in exon 14, which led to a predicted novel amino acid
change in codon 624 to methionine (Met) instead of valine
(Val; Val624Met) shown in Figure 2. In addition, two single
nucleotide  polymorphisms,  981A>G  (Val327Val)  and
1620T>T (Phe540Phe), were also found in this individual.
The proband’s brother also had the homozygous Val624Met
substitution.  As  expected,  the  proband’s  daughter  had  a
heterozygous Val624Met change.
Protein  analysis:  The  amount  of  soluble  protein  in  the
proband’s  cornea  was  similar  to  that  of  a  normal  control
cornea. The discernible individual bands in the SDS gels were
also similar and of an equivalent intensity (Figure 3). In a
normal human cornea, a peptide derived from the trypsin
digest of TGFBIp contained Val-624 (3491.28 Da). In the
proband’s cornea, this normal peptide was replaced with the
mutated  peptide  Met-624  (3539.29  Da).  The  mass  of  the
mutated peptide was 16 Da higher than expected because the
methionine  residue  was  oxidized.  The  tryptic  peptide
(Glu-611 – Arg-642) containing Val-624 was identified in the
normal human cornea and the mass of the peptide was 3491.28
Da (MH+). In the proband’s cornea, the Glu-611 – Arg-642
peptide was identified with a mass of 3539.29 Da (MH+). This
is consistent with a Val624Met mutation.
Figure 1. Slit-lamp photographs of the proband’s affected eye. A and
B: Slit-lamp photographs of the ropy lattice lines in the proband’s
affected eye at two different magnifications are shown. The proband
was 47 years old. C and D: Slit lamp photograph of the right and the
left eye of proband's brother showing multiple small geometric rod
shaped  lesions  in  the  posterior  corneal  stromal  (the  lesions  are
highlighted with arrowheads).
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A novel homozygous change in TGFBI was found in two
Figure 2. Partial nucleotide sequences of exon 14 of TGFBI in this
family. A: A normal sequence is shown, which has valine in codon
624. B: The proband and his brother had homozygous substitutions
in nucleotide 1870, which is predicted to alter the amino acid at codon
624 (Val624Met). C: The proband’s daughter had a heterozygous
substitution of valine to methionine in the same codon. The observed
nucleotide change in exon 14 of TGFBI has not been detected in the
general population.
family members with atypical asymmetric LCD and deep
corneal  stromal  opacities.  The  homozygous  nucleotide
change in exon 14 of TGFBI in this family not only coincided
with an atypical LCD but predicts a valine to methionine
change in the fas4 domain of the encoded TGFBIp, and this
was indeed found on a direct analysis of the cornea. This
homozygous nucleotide change is likely to be an important
disease-producing mutation because it changes an amino acid
residue in exon 14 from valine to methionine. Although both
amino acid residues are hydrophobic, methionine contains a
sulfur atom which is susceptible to oxidation and is slightly
more bulky. These properties may affect the folding of the
protein and hence its tertiary and quaternary structure. Perhaps
a homozygous mutation is needed to affect the folding of the
protein. This could explain why the 24-year-old heterozygous
daughter of the proband lacks symptoms of corneal disease.
Additionally,  this  region  of  exon  14  has  been  previously
associated with other mutations leading to corneal dystrophies
[7,10-12], thus a change in this exon is likely to be a disease-
Figure 3. Comparison of SDS-extracted proteins derived from the
proband and a normal human cornea. The extracted proteins were
analyzed by reduced SDS–PAGE and stained with coomassie blue.
The 64 kDa band in lanes 2 and 3 (see arrow) were excised, digested
with  trypsin,  and  identified  as  TGFBIp  by  MALDI  mass
spectrometry fingerprint analysis. Lane 1: molecular size markers;
Lane 2: normal human cornea; Lane 3: cornea of proband.
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497producing mutation. Stewart et al. [13] reported mutations on
either side of this family’s mutation in codon 622 and 626 in
three families with LCD. Only one of the reported mutations
produced unilateral disease (His626Arg). The disorder was
also late onset in most patients, and there was significant
asymmetry.
Schmitt-Bernard et al. [12] reported the same His626Arg
mutation in one family and a 9 bp insertion at position 1885
to position 1886 in exon 14 in another family with LCD.
Afshari et al. [10] also found the His626Arg mutation in
a family with bilateral normal onset LCD and a Gly623Asp
mutation in codon 14 in a family with Reis-Bücklers corneal
dystrophy (granular corneal dystrophy type III). Furthermore,
our reported mutation was not found in the 31 control samples
from 27 other families in which mutations in the exon 14 of
TGFBI gene were evaluated.
Patients with the different variants of LCD caused by
mutations  in  TGFBI  typically  have  bilateral,  symmetric,
translucent, delicate linear opacities that tend to be in the
anterior stroma, and epithelial erosions often form. Unilateral
LCD has been previously reported [14]. The linear and other
shaped opacities result from amyloid deposits, but the reason
for the amyloid accumulations remains poorly understood. In
those corneal amyloidoses caused by mutations in TGFBI, it
is clear that amyloid relates to mutations in specific codons.
Based on our findings in this family, the Val624Met
mutation in TGFBI seems to also play a role in this regard. It
is noteworthy that in addition to defects in TGFBI, corneal
amyloidoses also results from genetic defects in at least two
other genes (GSN, TACSTD2 [formerly called M1S1]) that
encode for different proteins [15,16].
Examining the mutated proteins encoded by the different
genes is potentially helpful in understanding the role that the
defect  plays  in  altering  the  structure  and  function  of  the
protein. In this case, the representative portion of cornea from
the proband contained normal quantities of TGFBIp and other
soluble  proteins,  but  the  analysis  of  the  tryptic  digest  of
TGFBIp  in  the  proband’s  cornea  disclosed  the  predicted
Val624Met  mutation.  Hence,  these  data  show  that  the
Val624Met TGFBIp mutant accumulated in the cornea. In
addition, since the peptide was recovered from a ~65 kDa
protein band in a reduced SDS gel, the observation suggests
that the accumulated protein was intact TGFBIp and not a
fragment of TGFBIp.
Heterozygous mutations in TGFBI have typically caused
corneal dystrophies. However, in the family reported here, the
novel  Val624Met  mutation  apparently  needs  to  be  in  a
homozygous state for clinical disease to become evident as
noted in the proband and his brother. Moreover, the proband’s
24-year-old daughter exhibited a heterozygous Val624Met
al.teration  in  TGFBI  but  had  no  reported  ophthalmic
abnormalities. A comparable situation has been observed in a
variation of LCD documented as LCD type III [17,18]. This
late onset variant of LCD was thought to have an autosomal
recessive mode of inheritance because it affected children of
parents  without  corneal  disease  [17],  but  subsequently  it
became established that affected persons had a homozygous
Leu527Arg  mutation  in  TGFBI  [19].  The  Leu527Arg
mutation,  however,  may  be  expressed  clinically  in  the
heterozygous state [20]. Future studies on other families with
LCD  will  hopefully  determine  whether  the  Val624Met
mutation  is  significant  in  the  pathogenesis  of  LCD  and
whether  a  homozygous  mutation  is  essential  for  disease
expression.
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